Localization of α-synuclein to mitochondria within midbrain of mice

NeuroReport

Volumn 18, Issue 15, 2007, Pages 1543-1546

  Li, Wen Wei ^a   Yang, Ru ^b   Guo, Jing Chun ^b   Ren, Hui Min ^b   Zha, Xi Liang ^c   Cheng, Jie Shi ^b   Cai, Ding Fang ^a,c  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

synuclein; Dopaminergic neuron; Mitochondria; Neurodegeneration; Parkinson's disease; Subcellular localization

Indexed keywords

ALPHA SYNUCLEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; MALE; MEMBRANE BINDING; MESENCEPHALON; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PARKINSON DISEASE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; DOPAMINE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; SUBCELLULAR FRACTIONS;

EID: 34748826792     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3282f03db4     Document Type: Article

References (23)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55:259-272.
2. Von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Progr Neurobiol 2004; 73:151-177.
3. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Inhibition of monoamine oxidase produces protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Nature 1984; 311:467-469.
4. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 1985; 82:2173-2177.
5. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002; 99:14524-14529.
6. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004; 186:158-172.
7. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157:401-410.
8. McNamara JO, Appel SH. Myeline basic protein phosphatase activity in rat brain. J Neurochem 1997; 29:27-35.
9. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000; 74:721-729.
10. Li JL, Wang D, Kaneko T, Shigemoto R, Nomura S, Mizuno N. The relationship between neurokinin-1 receptor and substance P in the medullary dorsal horn A light and electron microscopic immunohistochemical study in the rat. Neurosci Res 2000; 36:327-334.
11. Uversky VN. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 2003; 21:211-234.
12. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95:6469-6473.
13. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
14. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-108.
15. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295:865-868.
16. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404:394-398.
17. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287:1265-1269.
18. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002; 34:521-533.
19. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002; 99: 8968-8973.
20. Orth M, Tabrizi SJ, Tomlinson C, Messmer K, Korlipara LVP, Schapira AHV, et al. G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem Int 2004; 45:669-676.
21. Fornai F, Schulter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiqutin-proteasome system and a-synuclein. Proc Natl Acad Sci USA 2004; 102:3413-3418.
22. Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006; 21:541-548.
23. Beal MF. Commentary on 'Alpha-synuclein and mitochondria: a tangled skein'. Exp Neurol 2004; 186:109-111.